About Us

Science-led integrated drug discovery: medicinal and synthetic chemistry, computational chemistry, in vitro biosciences, DMPK, compound management and diversity and fragment libraries

BioAscent is a leading provider of integrated drug discovery services

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / MSD R&D site in Newhouse, Scotland, UK.

Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening (including HTS), medicinal and synthetic chemistry, computational chemistry and compound management, all with access to in-house diversity and fragment libraries.

Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications. As part of its compound management service, BioAscent currently holds and manages over 1.5 million compounds for our customers, in both liquid and solid formats.

Since 2013, the BioAscent team has been responsible for:

Over 150 biochemical, biophysical and cellular assays for drug discovery projects

Over 50 hit validation / characterisation projects

Over 30 hit-to-lead campaigns

Over 100,000 screening plates delivered to our global customers/partners

Integrated Drug Discovery


Science-led drug discovery

Get in Touch

Let's talk about how we can maximise your drug discovery success.

Contact